Preserving cardiovascular benefits of hormone replacement therapy

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 45, Issue 3 SUPPL., 2000, Pages 259-272

  Bush, Trudy L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Estrogen replacement therapy; Hormone replacement therapy, post menopausal

Indexed keywords

17ALPHA ESTRADIOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; CARBACHOL; CARBOHYDRATE; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; GLIBENCLAMIDE; INDOMETACIN; LEVONORGESTREL; LIPID; MEDROXYPROGESTERONE ACETATE; MEVINOLIN; NORETHISTERONE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHLORIDE; PROGESTERONE; PROPRANOLOL; PROSTAGLANDIN F2 ALPHA; SIMVASTATIN; TESTOSTERONE; VERAPAMIL;

ATHEROSCLEROSIS; BLOOD VESSEL REACTIVITY; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CHOLESTEROL METABOLISM; CONFERENCE PAPER; CORONARY ARTERY DISEASE; ESTROGEN THERAPY; HEART INFARCTION; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL;

CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MIDDLE AGED; PROGESTINS; RANDOMIZED CONTROLLED TRIALS;

EID: 0034124056     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. National Center for Health Statistics: Women's deaths from heart disease in 1994. NCHS, Vital Statistics Report, 1995
2. Barrett-Connor E, Bush TL: Estrogen and coronary heart disease in women. JAMA 1991;265:1861-1867
3. Barrett-Connor E, Grady D: Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998;19:55-72
4. Sullivan J, Vander Zwag R, et al: Estrogen replacement and coronary artery disease: Effect on survival in postmenopausal women. Arch Intern Med 1990:150:2557-2562
5. Brasch K: Nuclear protein modifications in vitellogenic rooster liver. Cell Mol Biol 1990;36:659-671
6. Brasch K, Peters KE: Nuclear protein, matrix and structural changes in rooster liver after estrogenic induction of vitellogenesis. Biol Cell 1985;54:109-122
7. Noteborn MHM, Bakker O, de Jonge MAW, et al: Differential estrogen responsiveness of the vitellogenin and apo very low density lipoprotein II genes in the rooster liver. J Steroid Biochem 1986;24:281-285
8. Bakker O, Arnberg AC, Notebum MHM, et al: Turnover products of the apo very low density lipoprotein II messenger RNA from chicken liver. Nucleic Acids Res 1988;16: 10109-10118
9. Luskey KL, Brown MS, Goldstein JL: Stimulation of the synthesis of very low density lipoproteins in rooster liver by estradiol. J Biol Chem 1974;249:5939-5947
10. 2+](i) during inhibition of coronary smooth muscle contraction by 17β-estradiol, progesterone, and testosterone. J Pharmacol Exp Ther 1999;291:44-52
11. 2+ entry mechanisms of coronary vasoconstriction. Arterioscler Thromb Vasc Biol 1999;19:1034-1040
12. Darkow DJ, Lu L, White RE: Estrogen relaxation of coronary artery smooth muscle is mediated by nitric oxide and cGMP. Am J Physiol 1997;272:H2765-H2773
13. Bhalla RC, Toth KF, Bhatty RA, et al: Estrogen reduces proliferation and agonist-induced calcium increase in coronary artery smooth muscle cells. Am J Physiol 1997;272: J1996-H2003
14. Ca channels through a cGMP-dependent mechanism. Circ Res 1995;77:936-942
15. Sudhir K, Chou TM, Mullen WL, et al: Mechanisms of estrogen-induced vasodilation: In vivo studies in canine coronary conductance and resistance arteries. J Am Coll Cardiol 1995; 26:807-814
16. Horwitz KB, Horwitz LD: Canine vascular tissues are targets for androgens, estrogens, progestins, and glucocorticoids. J Clin Invest 1982;69:750-758
17. Haarbo J: Hormone replacement therapy and cardiovascular disease: The rabbit model. Br J Obstet Gynaecol 1996;103: 49-52
18. Alexandersen P, Haarbo J, Sandholdt I, et al: Norethindrone acetate enhances the antiatherogenic effect of 17β-estradiol: A secondary prevention study of aortic atherosclerosis in ovariectomized cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 1998;18:902-907
19. Hegele-Hartung C, Fritzemeier K-H, Diel P: Effects of a pure antiestrogen and progesterone on estrogen-mediated alterations of blood flow and progesterone receptor expression in the aorta of ovariectomized rabbits. J Steroid Biochem Mol Biol 1997;637:237-249
20. Haarbo J, Leth-Espensen P, Stender S, et al: Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. J Clin Invest 1991;87: 1274-1279
21. Espeland MA, Applegate W, Furberg CD, et al: Estrogen replacement therapy and progression of intimal-medial thickness in the cartoid arteries of postmenopausal women. Am J Epidemiol 1995;142:1011-1019
22. Sbarouni E, Iliodromitis EK, Bofilis E, et al: Short-term estrogen reduces myocardial infarct size in oophorectomized female rabbits in a dose-dependent manner. Cardiovasc Drugs Ther 1998;12:457-462
23. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208
24. Sbarouni E, Kyriakides ZS, Kremastinos DTH: The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease. J Am Coll Cardiol 1998;32:1244-1250
25. Bush TL: The epidemiology of cardiovascular disease in postmenopausal women. Ann NY Acad Sci 1990;592: 263-271
26. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023
27. Hulley S, Grady D, Bush T, et al, for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-613
28. Bush TL: Lessons from HERS: The null and beyond. J Womens Health 1998;7:781-783
29. Barrett-Connor E, Slone S, Greendale G, et al: The postmenopausal estrogen/progestin interventions study: Primary outcomes in adherent women. Maturitas 1997;27:261-274
30. Espeland MA, Marcovina SM, Miller V, et al: Effect of postmenopausal hormone therapy on lipoprotein (a) concentration. Circulation 1998;97:979-986
31. Tilly-Kiesi M, Lappi M, Puolakka J, et al: Different effects of continuous oestrogen-progestin and transdermal oestrogen with cyclic progestin regimens on low-density lipoprotein subclasses. Eur J Clin Invest 1996;26:1125-1133
32. Herrington DM, Werbel BL, Riley WA, et al: Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease. J Am Coll Cardiol 1999;33:2030-2037
33. Kannel WB, Wolf PA, Castelli WP, et al: Fibrinogen and risk of cardiovascular disease: The Framingham Study. JAMA 1987;25:1183-1186
34. Rosenson RS, Tangney CC, Mosca LJ: Hormone replacement therapy improves cardiovascular risk by lowering plasma viscosity in postmenopausal women. Arterioscler Thromb Vasc Biol 1998;18:1902-1905
35. Beale CM, Collins P: The menopause and the cardiovascular system. Baillieres Clin Obstet Gynaecol 1996;10:483-513
36. Stevenson JC, Crook D, Godsland IF, et al: Hormone replacement therapy and the cardiovascular system: Nonlipid effects. Drugs 1994;47:35-41